[{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"National Institute of General Medical Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sinopia Biosciences \/ National Institute of General Medical Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Sinopia Biosciences \/ National Institute of General Medical Sciences"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"SB-0110","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinopia Biosciences \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Sinopia Biosciences \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"SB-0110","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinopia Biosciences \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Sinopia Biosciences \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"NIDCR","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinopia Biosciences \/ NIDCR","highestDevelopmentStatusID":"2","companyTruncated":"Sinopia Biosciences \/ NIDCR"}]

Find Clinical Drug Pipeline Developments & Deals by Sinopia Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Details : The funding aims to support the company in discovering novel small molecules and identifying promising treatment candidates for oral mucositis.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Undisclosed

December 09, 2024

Lead Product(s) : Undisclosed

Therapeutic Area : Gastroenterology

Highest Development Status : Discovery

Sponsor : NIDCR

Deal Size : $2.2 million

Deal Type : Funding

blank

02

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Details : The proceeds will advance its computational drug discovery LEarn And DiScover (LEADS™) platform and explore applications in oncology and immunology.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Undisclosed

May 30, 2024

Lead Product(s) : Undisclosed

Therapeutic Area : Oncology

Highest Development Status : Discovery Platform

Sponsor : National Institute of General Medical Sciences

Deal Size : Undisclosed

Deal Type : Funding

blank

03

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Details : The funding will be used to advance SB-0110, a novel, proprietary small molecule with a unique mechanism of action that was identified using Sinopia’s LEADS™ platform, into Phase I clinical trials.

Product Name : SB-0110

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

April 19, 2023

Lead Product(s) : SB-0110

Therapeutic Area : Neurology

Highest Development Status : Preclinical

Sponsor : Michael J. Fox Foundation for Parkinson’s Research

Deal Size : $2.0 million

Deal Type : Funding

blank

04

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Details : The funding will be used to advance SB-0110, a novel, proprietary small molecule with a unique mechanism of action that was identified using Sinopia’s LEADS™ platform, into Phase II clinical trials.

Product Name : SB-0110

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

April 19, 2023

Lead Product(s) : SB-0110

Therapeutic Area : Neurology

Highest Development Status : Preclinical

Sponsor : National Institute of Neurological Disorders and Stroke

Deal Size : $3.3 million

Deal Type : Funding

blank